Biotech routes for valorisation of residual biomass

Expected Outcome

Successful proposals will contribute to the implementation of the EU initiative on Biotechnology and Biomanufacturing and the EU Life Sciences Strategy as well as the updated EU Bioeconomy Strategy, the Clean Industrial Deal, the European Chemical Industry Action Plan, the upcoming EU Biotechnology and Circular Economy Acts.

Projects results are expected to contribute to the following expected outcomes:

• Increased added value of residual biomass for biorefinery applications.
• Availability of a wider portfolio of sustainable bio-based products via industrial biotech.
• Robust, scalable and efficient biotech process(es) applicable to residual biomass.

Scope

Diversifying biomass feedstock resources for bio-based products is key to contribute to resilience and strategic autonomy of bio-based operations. Industrial biotechnologies have showcased that they can play a key role to address residual biomass into valuable bio-based products. However, scaling up from research to demo scale requires addressing systemic and technical challenges. This entails the integration of adequate pretreatment and conversion processes, tailored to the targeted residual biomass and its composition variability, in order to achieve high yield, titre and selectivity. At the same time, it requires that these processes are scalable and sustainable. Moreover, effective logistics are needed to mobilise the residual biomass, requiring cooperation with primary producers, waste management operators and other biomass providers.

Proposals under this topic should:

• Demonstrate (at least TRL 6) efficient biotechnology based processes to convert residual biomass streams into bio-based chemicals, intermediates, polymers, materials, ingredients[1]and/or enzymes. The topic focuses on processes in which biotechnology is the key enabling technology; the integration of supporting unit operations based on technologies other than biotechnology is in scope. Optimisation of selected cells, enzymes and/or microorganisms, including microbiomes, is also in scope. The feedstock in scope includes:
• Forestry and agricultural residues and/or side streams from the processing of forestry and agricultural biomass (including livestock-based ones such as manure and animal byproducts),
• residues from aquatic biomass, including from fisheries, micro/macro algae production and aquaculture,
• urban and/or industrial bio-based waste and side-streams (including food industry waste and side-streams, cellulose from post-consumer and post-industrial waste, urban biowaste and sewage sludge, and other bio-based waste/side-streams from industrial operations including wood and pulp and paper industry),
• mixed streams from the above.
• Integrate optimised biomass pretreatment/fractionation processes tailored to selected residual biomass and optimise (energy)-efficient separation and/or purification process step(s) across the value chain. The valorisation of by-products and side streams across the value chain via the cascading approach is in scope.
• Validate (at TRL 5 and above) conversion (or use) of biorefinery product(s) into end-products proving to fulfil market requirements for selected applications sectors.
• Address resource efficiency and circularity. When pursuing circular models, ensure that neither pathogens nor contaminants are injected back in the loop, to avoid negative effects on human health and the environment.

In addition to the specific requirements applicable for the type of action, as described in section 2.2.3.1 of the CBE JU Annual Work Programme 2026[2], proposals under this topic should:

• Under the multi-actor approach (MAA), ensure the sufficient involvement of feedstock producers/managers for residual feedstock supply.
• Optimise logistic models (including sourcing, storage and transport) of residual feedstock, minimising distances and costs. Ensure seamless integration with biomass providers, while promoting win-win business models.
• Perform a risk assessment on impacts, potentially deriving from the use of biotechnology, on human safety, biodiversity as well as environmental safety and identify adequate mitigation measures. Assess the adequacy of policy and regulatory means to manage these risks and provide recommendations to overcome potential identified bottlenecks.
• Ensure complementarities with past and ongoing R&I projects addressing similar challenges, including projects funded under Horizon 2020/Horizon Europe (under Cluster 6 and other Clusters of Horizon Europe) and BBI JU/CBE JU projects.

[1] Ingredients in scope include feed/food ingredients, bioactives, ingredients for cosmetics, home and/or personal care, nutraceutical sectors, fertilisers including biostimulants.

[2] https://www.cbe.europa.eu/reference-documents